Abbott Laboratories (NYSE:ABT) traded ~3% lower in the premarket on Wednesday after the MedTech giant’s Q3 2025 results slightly fell short of Street forecasts for revenue and the company narrowed its full-year earnings outlook.
North Chicago, Illinois-based Abbott (NYSE: